
© 2024 Der Aktionär
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo | ||
Mo | Don't overlook the impact of pharma tariffs, says an analyst. Where we stand on Bristol Myers | ||
Mo | Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO), Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products for Human... ► Artikel lesen | |
Mo | BMO maintains Bristol-Myers $61 target, Market Perform rating | ||
Sa | Why Bristol-Myers Squibb Co. (BMY) Went Up On Friday? |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | Cantor Fitzgerald maintains overweight on Immatics stock | ||
Do | Immatics GAAP EPS of €0.14 beats, revenue of $161.9M | ||
Do | Immatics N.V. - 6-K, Report of foreign issuer | ||
Do | Immatics Announces Full Year 2024 Financial Results and Business Update | Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203... ► Artikel lesen | |
Do | Immatics N.V. - 20-F, Annual and transition report of foreign private issuers |
Unternehmen / Aktien | Kurs | % |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | 55,10 | -0,14 % |
IMMATICS NV | 3,772 | +1,89 % |